相关实验视频

Updated: May 28, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

一种针对GPIbα的新型抗体抑制了血小板功能和血栓形成,而不会增加出血

Lili Zhao¹, Jiahao Du¹, Yuxin Jin¹

¹Jiangsu Institute of Hematology, Cyrus Tang Medical Institute, The First Affiliated Hospital and Collaborative Innovation Center of Hematology, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, National Clinical Research Center for Hematological Diseases, Suzhou, China.

International journal of biological macromolecules

|February 9, 2025

概括

人性化抗体SZ003-Fab通过向糖蛋白Ibα (GPIbα) 有效地抑制血小板聚合和动脉血栓形成. 这种新型抗血栓性药物显示出治疗血栓的前景,而不会引起血栓细胞减小或出血.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

动脉血栓是心血管疾病的主要原因之一.
糖蛋白Ibα (GPIbα) 是动脉血栓形成的关键启动剂,也是抗血小板药物的标.
现有的抗GPIbα药物没有取得临床成功.

研究的目的:

开发一种新的人性化的抗GPIbα抗体,用于治疗动脉血栓症.
评估人性化抗体SZ003及其Fab片段 (SZ003-Fab) 的疗效和安全性.

主要方法:

产生小鼠抗人类GPIbα抗体 (9C9).
构建和验证仿制 (1A09) 和人性化 (SZ003) 抗体.
在体外和体内测试使用ELISA,西部斑块,血小板聚合试验和血栓形成模型.
评估SZ003-Fab对血小板清除,出血时间和细胞毒性的评估.

主要成果:

SZ003对GPIbα表现出特异性和亲和力,抑制了血小板聚合.
在体内,SZ003-Fab有效抑制了GPIbα介导的血小板聚合和血栓形成.
SZ003-Fab没有诱导血小板清除,延长出血时间,或表现出细胞毒性.

结论:

人性化抗GPIbα抗体SZ003的Fab片段是一种强大的血小板激活和血栓形成的抑制剂.
SZ003-Fab显示出显著的临床潜力,作为一种安全有效的抗血栓剂,用于与动脉血栓相关的疾病.

关键词:

抗血小板药物可以抗血小板.对于GPIbα来说,这是一个很大的问题.人性化抗体的人性化抗体血小板是血小板的组成部分.血栓形成的原因之一是血栓形成.

更多相关视频

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...